ArticleTheranostics2019
A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment.
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 67 citations in OpenAlex.
- Bioresponsive engineered nanoparticles for immunomodulation.BMC medicine · 2025Review
- ROS homeostasis in cell fate, pathophysiology, and therapeutic interventions.Molecular biomedicine · 2025Review
- Restoring mucosal barrier homeostasis by in situ formation of a living-synthetic therapeutic coating.Nature communications · 2025Article
- Emerging nanocarrier systems for the enhanced delivery of active pharmaceutical ingredients to the intestine.Nanomedicine (London, England) · 2025Review
- A tumor-targeting black phosphorus-based nanoplatform for controlled chemo-photothermal therapy of breast cancer.Materials today. Bio · 2025Article
- Microalgae-carrying nanomedicine for bioadhesive drug delivery for treating chemotherapy-induced intestinal injury.Asian journal of pharmaceutical sciences · 2025Article
- Application of Nanomedicine in Tumor Targeting Inflammatory Pathway.Current medicinal chemistry · 2025Review
- Reactive oxygen species responsive double-locked liposome collaborative photodynamic therapy for reducing electrical conduction recurrence after radiofrequency catheter ablation.International journal of pharmaceutics: X · 2024Article
- Recent advances in nanoadjuvant-triggered STING activation for enhanced cancer immunotherapy.Heliyon · 2024Review
- Macrocycle-Based Supramolecular Drug Delivery Systems: A Concise Review.Molecules (Basel, Switzerland) · 2024Review
- Plant-derived vesicle-like nanoparticles: A new tool for inflammatory bowel disease and colitis-associated cancer treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Treatment of colorectal cancer by anticancer and antibacterial effects of hemiprotonic phenanthroline-phenanthrolineAsian journal of pharmaceutical sciences · 2023Article
- Multifunctional nanoparticle for cancer therapy.MedComm · 2023Review
- Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach.Molecules (Basel, Switzerland) · 2022Review
- Nano-Drug Delivery Systems Based on Different Targeting Mechanisms in the Targeted Therapy of Colorectal Cancer.Molecules (Basel, Switzerland) · 2022Review
- Differentially Infiltrated Identification of Novel Diagnostic Biomarkers Associated with Immune Infiltration in Nasopharyngeal Carcinoma.Disease markers · 2022Article
- Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease.Journal of inflammation research · 2021Review
- Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment.International journal of nanomedicine · 2021Review
- Microenvironment Activatable Nanoprodrug Based on Gripper-like Cyclic Phenylboronic Acid to Precisely and Effectively Alleviate Drug-induced Hepatitis.Theranostics · 2021Article
- Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colitis-associated colon cancer (CAC) is a widely recognized cancer, while treatment with the existing chemotherapeutic drugs affords limited clinical benefits. Herein we proposed a site-specific, combination nanotherapy strategy for targeted treatment of CAC by the oral route.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.